Ahmed Sawas, MD

Ahmed Sawas, MD is an Assistant Professor of Medicine and Experimental Therapeutics, in the Center of Lymphoid Malignancies with an appointment to the Division of Hematology/Oncology and the Division of Experimental Therapeutics at the Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital in New York City.

Dr. Sawas completed his pharmacology degree from Stony Brook University and received his medical degree from the State University of New York - Health Science Center at Brooklyn, College of Medicine in New York. He completed his internship and residency in internal medicine at the St. Vincent’s Catholic Medical Center/ New York Medical College. Dr. Sawas completed his fellowship in hematology and medical oncology at the New York University Medical Center. His research interests are focused on the development of novel therapies for lymphoma, as well as prognostic and predictive biomarkers of early response. Dr. Sawas serves as the principal investigator on many clinical trials and has authored or coauthored many publications and abstracts in peer reviewed journals on the diagnosis and treatment of lymphoma.

Additionally, Dr. Sawas is a leader in the development of new immunotherapy agents for the treatment of lymphoma. Targeted therapies attack tumor surface proteins, aberrant epigenetic, regulation, signaling or cell survival pathways, or the microenvironment. This allows for a customized approach to cancer therapy while minimizing toxicity.  AGS67E is an antibody-drug-conjugate that targets CD37, commonly expressed on tumor cells in non-Hodgkin lymphomas. Dr. Sawas led the initial clinical trial in lymphoma patients that has shown to be safe and has impressive activity. This drug is in the second stage of development and is being investigated in diffuse large B-cell lymphoma, peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Along with Dr. Geskin, from the department of Dermatology, Dr. Sawas has established a multidisciplinary team focused on the treatment of skin lymphomas. The team offers integrated, expert treatment for patients with cutaneous lymphomas, including mycosis fungoides, Sezary syndrome, CD30+ lymphoproliferative disorders (lymphomatoid papulosis and anaplastic large cell lymphoma), subcutaneous panniculitis-like T-cell lymphoma, gamma-delta T-cell lymphoma, CD8+ aggressive epidermotropic T-cell lymphoma, NK/T-cell lymphoma, other unspecified cutaneous peripheral T-cell lymphomas, and cutaneous B-cell lymphomas. We are committed to the introduction of novel immunotherapies with high efficacy and low toxicity for these patients.  

Dr. Sawas is a member of the American Society of Hematology and the American Society of Clinical Oncology. He is focused on helping patients with lymphoma.